Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

7.7%

1 terminated/withdrawn out of 13 trials

Success Rate

90.9%

+4.4% vs industry average

Late-Stage Pipeline

31%

4 trials in Phase 3/4

Results Transparency

80%

8 of 10 completed trials have results

Key Signals

1 recruiting8 with results

Enrollment Performance

Analytics

Phase 2

7(53.8%)

Phase 3

3(23.1%)

Phase 1

2(15.4%)

Phase 4

1(7.7%)

13Total

Phase 2(7)

Phase 3(3)

Phase 1(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (13)

Showing 13 of 13 trials

NCT06971939Phase 4Recruiting

Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants

Role: lead

NCT06397131Phase 3Active Not Recruiting

A Study to Determine the Safety and Efficacy of NT-501 With MHFM

Role: lead

NCT03071965Phase 2Completed

Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel)

Role: lead

NCT00447980Phase 2Completed

A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa

Role: lead

NCT00447954Phase 2Completed

A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degeneration

Role: lead

NCT04729972Phase 2Completed

Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2

Role: lead

NCT03319849Phase 3Completed

A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol B

Role: lead

NCT03316300Phase 3Completed

A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A

Role: lead

NCT00447993Phase 2Completed

A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa

Role: lead

NCT01530659Phase 2Completed

Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa

Role: lead

NCT02228304Phase 1Terminated

Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

Role: lead

NCT01949324Phase 2Completed

A Phase 2 Multicenter Randomized Clinical Trial of CNTF for MacTel

Role: lead

NCT01327911Phase 1Completed

Ciliary Neurotrophic Factor (CNTF) Safety Trial in Patients With Macular Telangiectasia (Mactel)

Role: lead

All 13 trials loaded